Early results from REFLECTION, a real-world study, mirrored results for Grail Inc.'s multi-cancer early detection (MCED) assay in clinical trials, according to a presentation at the 2024 Early Detection of Cancer Conference. The study, conducted at U.S. Department of Veterans Affairs (VA) sites, focuses on the real-world application of the Galleri test, which screens for multiple cancers in asymptomatic individuals.
Modifi Biosciences Inc. has come a long way very quickly. Spun out of Yale University in 2021, it published data on DNA in Science in July 2022, and now it’s being acquired by Merck & Co. Inc. for $30 million up front. Ultimately, Modifi shareholders could receive milestones of up to $1.3 billion.
Beijing Konruns Pharmaceutical Co. Ltd. has identified histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
Fibroblast activation protein (FAP) is absent or expressed at a very low level in normal tissues. However, it is overexpressed in around 80% of solid tumor stroma.
Rakovina Therapeutics Inc. has obtained a short-list of recommended drug candidates from an initial artificial intelligence (AI) screening effort using the Deep Docking AI platform under a collaboration with the University of British Columbia.
At the European Association of Nuclear Medicine meeting, Monopar Therapeutics Inc. presented the preclinical characterization of MNPR-101, a first-in-class urokinase-type plasminogen activator receptor (uPAR)-targeting radiopharmaceutical agent with high stability in vivo and more than 1 week of shelf-life in its labeled form, [177Lu]-MNPR-101.
FMS‐like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase validated as a therapeutic target for acute myeloid leukemia (AML) and regarded as an indicator of poor prognosis. Unfortunately, current FLT3 inhibitors, such as midostaurin, quizartinib or gilteritinib, often lead to myelosuppression or cardiovascular toxicity.
RSS
